LONDON, UK / ACCESSWIRE / April 12, 2019 / Pixium Vision (PARIS: PIX) is developing Prima, a potentially breakthrough wireless sub-retinal implant that generates electrical impulses at the retinal bipolar cell level to restore a form of central visual perception. Pixium is on track to start an EU pivotal study for its Prima bionic vision system (BVS) in H219 for the treatment of advanced dry age-related macular degeneration (Dry-AMD) involving geographic atrophy (GA). This follows the release of positive six-month data in January 2019 for its five-patient EU feasibility study. Using a risk-adjusted NPV model, we obtain a pipeline rNPV (including net cash) of €99.5m, vs €99.0m previously.
We believe Pixium's cash on hand should be sufficient for it to maintain its operations into Q220. We continue to estimate that Pixium will raise €75m through 2021 to fund Prima development. As per Edison policy, we model these as debt financing. We continue to value Pixium using an rNPV approach, employing a 12.5% cost of capital and applying a 15% probability of success estimate for Prima. Following minor changes to our market size, forex and EU pricing assumptions, we now obtain a pipeline rNPV (enterprise value) of €91.7m, up from €91.2m, previously. After including €7.8m net cash at 31 December 2018, we obtain an equity valuation of €99.5m, or €4.49 per share (compared to €4.50 previously).
Click here to view the full report.
All reports published by Edison are available to download free of charge from its website
About Edison: Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world-renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisers and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
Edison is authorised and regulated by the Financial Conduct Authority.
Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.
For more information please contact Edison:
Pooya Hemami, CFA, +1 646 653 7026
Maxim Jacobs, CFA, +1 646 653 7027
Learn more at www.edisongroup.com and connect with Edison on:
SOURCE: Edison Investment Research Limited